Keratoconjunctivitis Sicca Clinical Trial
Official title:
A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease
NCT number | NCT02665234 |
Other study ID # | MIM-726 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | January 2016 |
Est. completion date | March 2017 |
Verified date | August 2019 |
Source | Mimetogen Pharmaceuticals USA, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye disease.
Status | Completed |
Enrollment | 400 |
Est. completion date | March 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Be at least 18 years of age. - Provided written informed consent. - Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye Exclusion Criteria: - Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) at Visit 1. - Be diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months. - Have any planned ocular and/or lid surgeries over the study period. - Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit . - Have an uncontrolled systemic disease. - Be a woman who is pregnant, nursing or planning a pregnancy. - Be a woman of childbearing potential who is not using an acceptable means of birth control - Have a known allergy and/or sensitivity to the test article or its components. - Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study - Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits |
Country | Name | City | State |
---|---|---|---|
United States | MIM-726 Investigational Site | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Mimetogen Pharmaceuticals USA, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Corneal Fluorescein Staining Using The Ora Calibra Scale | An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE) | Day 57 | |
Primary | Ocular Discomfort Using The Ora Calibra Scale | A patient-reported subjective assessment of ocular discomfort recorded at each of the 5 office visits throughout the treatment period | Day 57 | |
Secondary | Total Corneal Fluorescein Staining Using The Ora Calibra Scale | An assessment of the total corneal fluorescein staining using the Ora Calibra Scale both immediately prior to and immediately following exposure to a challenge in a controlled adverse environment (CAE) | Day 15 | |
Secondary | Ocular Surface Disease Index | Day 57 | ||
Secondary | Ocular Dryness Using The Ora Calibra Scale | A patient-reported subjective assessment of ocular dryness recorded twice daily over the complete treatment period. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05618730 -
Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B
|
Phase 1 | |
Completed |
NCT02254265 -
Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
|
Phase 2/Phase 3 | |
Completed |
NCT00883649 -
Efficacy and Safety Study of Nutritional Supplements for Treatments of Dry Eye
|
N/A | |
Completed |
NCT00717418 -
Efficacy Study of Cyclosporine Ophthalmic Emulsion in Patients With Dry Eye Disease
|
N/A | |
Completed |
NCT00128245 -
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
|
Phase 2 | |
Enrolling by invitation |
NCT03436576 -
Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
|
Phase 3 | |
Completed |
NCT04147650 -
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT01733992 -
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
|
Phase 1 | |
Completed |
NCT00987727 -
Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye
|
Phase 4 | |
Completed |
NCT00788229 -
Efficacy and Safety Study of ATs in Patients With Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00554879 -
Acupuncture Treatment of Dry Eye
|
N/A | |
Completed |
NCT00407043 -
Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
|
Phase 4 | |
Completed |
NCT00001731 -
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
|
Phase 2 | |
Recruiting |
NCT03953703 -
Levocarnitine for Dry Eye in Sjogren's Syndrome
|
Phase 2 | |
Withdrawn |
NCT03398018 -
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
|
Phase 4 | |
Recruiting |
NCT02066896 -
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
|
Phase 3 | |
Completed |
NCT02139033 -
A Phase 4 Study Investigating the Efficacy of Retaineā¢ in Managing Signs and Symptoms Associated With Dry Eye Syndrome
|
Phase 4 | |
Terminated |
NCT01213342 -
Omega-3 Fatty Acid Supplements and Dry Eye
|
N/A | |
Completed |
NCT00201981 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 | |
Completed |
NCT00201955 -
Study of Rebamipide Eye Drops to Treat Dry Eye
|
Phase 3 |